Walleye Capital’s Xenon Pharmaceuticals XENE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-76,955
Closed -$4.65M – 6249
2026
Q2
$4.65M Buy
+76,955
New +$4.27M 0.02% 870
2026
Q1
– Sell
-19,587
Closed -$878K – 5069
2025
Q4
$878K Buy
+19,587
New +$823K ﹤0.01% 2551
2025
Q1
– Sell
-221,982
Closed -$8.7M – 5238
2024
Q4
$8.7M Buy
221,982
+117,022
+111% +$4.84M 0.02% 722
2024
Q3
$4.13M Buy
+104,960
New +$4.23M 0.01% 1325
2024
Q1
– Sell
-5,054
Closed -$233K – 5959
2023
Q4
$233K Sell
5,054
-120,974
-96% -$4.27M ﹤0.01% 3576
2023
Q3
$4.31M Buy
126,028
+36,324
+40% +$1.36M 0.01% 1144
2023
Q2
$3.45M Sell
89,704
-15,628
-15% -$621K 0.01% 961
2023
Q1
$3.77M Buy
105,332
+18,815
+22% +$695K 0.06% 420
2022
Q4
$3.41M Sell
86,517
-1,454
-2% -$52.9K 0.06% 369
2022
Q3
$3.18M Sell
87,971
-73,956
-46% -$2.66M 0.06% 348
2022
Q2
$4.93M Buy
161,927
+7,619
+5% +$230K 0.14% 175
2022
Q1
$4.72M Buy
154,308
+82,324
+114% +$2.46M 0.13% 173
2021
Q4
$2.25M Buy
+71,984
New +$2.15M 0.07% 303
2018
Q3
$101K Buy
+7,647
New +$88.6K 0.05% 257

Other funds holding XENE

Walleye Capital's XENE Position: Q3 2026 in Review

Walleye Capital sold out of Xenon Pharmaceuticals (XENE) in Q3 2026, closing a stake of 76,955 shares — an estimated $4.65M sold.

Walleye Capital first reported a position in XENE in Q3 2018 and held it in 14 quarters. The position peaked at $8.7M in Q4 2024. 285 funds tracked by Wall St. Rank hold XENE as of Q3 2026.

  • Walleye Capital reported no remaining Xenon Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Walleye Capital sold 76,955 Xenon Pharmaceuticals shares in Q3 2026, an estimated $4.65M.
  • Walleye Capital first reported a position in Xenon Pharmaceuticals in Q3 2018 and held it in 14 quarters.
  • Walleye Capital's Xenon Pharmaceuticals position peaked at $8.7M in Q4 2024.
  • 285 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q3 2026.

Based on Walleye Capital's 13F filing for Q3 2026, filed 13 Nov 2026.